N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide

C39H59ClN4O7S — CID 153341433

IUPACN-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide
SMILESCCCc1cc(Cl)ccc1C1COc2ccc(C(C)O)cc2N(CC2CCC2C(/C=C/CCN(C)C(C)=O)OCCOC)C1.CN(C)S(=O)NC=O
InChIInChI=1S/C36H51ClN2O5.C3H8N2O2S/c1-6-9-28-20-31(37)13-15-32(28)30-23-39(34-21-27(25(2)40)12-16-36(34)44-24-30)22-29-11-14-33(29)35(43-19-18-42-5)10-7-8-17-38(4)26(3)41;1-5(2)8(7)4-3-6/h7,10,12-13,15-16,20-21,25,29-30,33,35,40H,6,8-9,11,14,17-19,22-24H2,1-5H3;3H,1-2H3,(H,4,6)/b10-7+;
InChIKeyICOBJJUPQXUXKV-HCUGZAAXSA-N
MW763.44 g/mol
LogP5.68
Rot. Bonds18

About N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide

N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide (PubChem CID 153341433) has the molecular formula C39H59ClN4O7S and a molecular weight of 763.44 g/mol. Its IUPAC name is N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide.

Molecular Properties

Compound NameN-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide
PubChem CID153341433
Molecular FormulaC39H59ClN4O7S
Molecular Weight763.44 g/mol
Exact Mass762.38
IUPAC NameN-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide
SMILESCCCc1cc(Cl)ccc1C1COc2ccc(C(C)O)cc2N(CC2CCC2C(/C=C/CCN(C)C(C)=O)OCCOC)C1.CN(C)S(=O)NC=O
InChIInChI=1S/C36H51ClN2O5.C3H8N2O2S/c1-6-9-28-20-31(37)13-15-32(28)30-23-39(34-21-27(25(2)40)12-16-36(34)44-24-30)22-29-11-14-33(29)35(43-19-18-42-5)10-7-8-17-38(4)26(3)41;1-5(2)8(7)4-3-6/h7,10,12-13,15-16,20-21,25,29-30,33,35,40H,6,8-9,11,14,17-19,22-24H2,1-5H3;3H,1-2H3,(H,4,6)/b10-7+;
InChIKeyICOBJJUPQXUXKV-HCUGZAAXSA-N
XLogP5.68
TPSA120.88 Ų
H-Bond Donors2
H-Bond Acceptors8
Rotatable Bonds18
Heavy Atoms52
Complexity

Lipinski Rule of Five

2 violations

RuleValue
MW ≤ 500763.44
LogP ≤ 55.68
H-Bond Donors ≤ 52
H-Bond Acceptors ≤ 108

Computed Properties (RDKit)

Structural Alerts{'alert_name': 'aldehyde', 'substructure': 'N/A'}, {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'isolated_alkene', 'substructure': 'N/A'}

Analyze N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide?
The IUPAC name of N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide (CID 153341433) is N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide.
What is the SMILES notation for N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide?
The canonical SMILES for N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide is CCCc1cc(Cl)ccc1C1COc2ccc(C(C)O)cc2N(CC2CCC2C(/C=C/CCN(C)C(C)=O)OCCOC)C1.CN(C)S(=O)NC=O.
What is the InChIKey of N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide?
The InChIKey is ICOBJJUPQXUXKV-HCUGZAAXSA-N. The full InChI is InChI=1S/C36H51ClN2O5.C3H8N2O2S/c1-6-9-28-20-31(37)13-15-32(28)30-23-39(34-21-27(25(2)40)12-16-36(34)44-24-30)22-29-11-14-33(29)35(43-19-18-42-5)10-7-8-17-38(4)26(3)41;1-5(2)8(7)4-3-6/h7,10,12-13,15-16,20-21,25,29-30,33,35,40H,6,8-9,11,14,17-19,22-24H2,1-5H3;3H,1-2H3,(H,4,6)/b10-7+;.
What are the key properties of N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide?
N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide has a molecular weight of 763.44 g/mol, XLogP of 5.68, 18 rotatable bonds, 2 hydrogen bond donors, and 8 hydrogen bond acceptors.
Where does this data come from?
All data for N-[(E)-5-[2-[[3-(4-chloro-2-propylphenyl)-7-(1-hydroxyethyl)-3,4-dihydro-2H-1,5-benzoxazepin-5-yl]methyl]cyclobutyl]-5-(2-methoxyethoxy)pent-3-enyl]-N-methylacetamide;N-dimethylsulfinamoylformamide is sourced from PubChem (CID 153341433), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).